Pacira Biosciences Inc (PCRX) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
Pacira Biosciences Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Pacira Biosciences Inc's ROI in the second quarter of 2026? Pacira Biosciences inc achieved a return on average invested assets (ROI) of 1.29 % in its second quarter of 2026, this is above PCRX's average return on investment of -6.35%. Pacira Biosciences Inc invested over the 12 months ending in its second quarter of 2026 $1,139 million
ROI has improved compared to 0.44% in the first quarter of 2026, due to net income growth.
Within the Healthcare sector 10 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 2362 to 2390.
Pacira BioSciences: A Strategic Move Towards Strengthening Shareholder Value Amidst ChallengesIn a rapidly evolving biopharmaceutical landscape, Pacira BioSciences, Inc. (Nasdaq: PCRX) has made significant strides to enhance its value for shareholders. Recently, the company announced a $300 million aggregate share repurchase authorization, reiterating its confidence in its 5x30 plan, a strategic framework aimed at driving sustainable growth and profitability.Despite facing some financial hurdles, including a cumulative net loss of $100 million within the 12 months ending in the fourth quarter of 2024, Pacira’s management remains optimistic about the company s potential. The recorded negative return on investment (ROI) of -7.24% places Pacira behind 164 other companies within the healthcare sector that have shown higher returns. However, the overall ROI ranking for the company has improved significantly, moving from 2864 in the previous quarter to 1955 as of December 31, 2024.
Shareholders Alerted as Levi and Korsinsky Announces Lead Plaintiff Deadline in Pacira BioSciences Lawsuit New York, February 21, 2025 Levi and Korsinsky, LLP has issued a notification to investors in Pacira BioSciences, Inc. (Pacira or the Company), regarding a class action securities lawsuit currently in motion. Shareholders are reminded of the upcoming deadline of March 14, 2025, to register as lead plaintiffs. Pacira BioSciences, listed on NASDAQ under the ticker PCRX, has drawn legal scrutiny following a challenging financial year.The company reported a cumulative net loss amounting to $105 million over 12 months, concluding in the third quarter of 2024. This financial performance has resulted in a negative return on investment (ROI) of -7.35%. Such a performance places the company at a disadvantage within the healthcare sector, where 218 other entities have reported superior ROI metrics.
In a strategic move signaling its commitment to innovation and growth, Pacira Biosciences has announced new five-year objectives designed to expedite its transformation into a leading biopharmaceutical entity. With a robust preliminary unaudited revenue projection for 2024 at $701.0 million, the company is poised to leverage this financial momentum to enhance its research and development capabilities, particularly in the realm of pain management and chronic illness treatment.At the recent ACR Convergence annual meeting, Pacira debuted findings centered around PCRX-201, its investigational product aimed at addressing moderate to severe osteoarthritis of the knee—one of the most prevalent degenerative joint diseases impacting millions globally. The ongoing challenge in treating osteoarthritis often lies in the inadequacy of existing management strategies, which range from pharmacological interventions to physical rehabilitation and, in severe cases, surgical options. Amidst these traditional methods, PCRX-201 emerges as a beacon of hope, boasting positive preliminary results concerning both safety and efficacy.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
